ICA Group Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

ICA Group Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-200	Closed	-$17.5K	–	841
2024 Q1	$17.5K	Hold	200	–	–	﹤0.01%	783
2023 Q4	$19.3K	Buy	+200	New	+$17.7K	﹤0.01%	733
2023 Q3	–	Sell	-200	Closed	-$17.3K	–	336
2023 Q2	$17.3K	Hold	200	–	–	﹤0.01%	724
2023 Q1	$19.4K	Sell	200 -100	-33%	-$10.4K	﹤0.01%	671
2022 Q4	$31K	Buy	+300	New	+$28.2K	0.01%	604

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

ICA Group Wealth Management's BMRN Position: Q2 2024 in Review

ICA Group Wealth Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2024, closing a stake of 200 shares — an estimated $17.5K sold.

ICA Group Wealth Management first reported a position in BMRN in Q4 2022 and held it in 5 quarters. The position peaked at $31K in Q4 2022. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2024.

ICA Group Wealth Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
ICA Group Wealth Management sold 200 BioMarin Pharmaceuticals shares in Q2 2024, an estimated $17.5K.
ICA Group Wealth Management first reported a position in BioMarin Pharmaceuticals in Q4 2022 and held it in 5 quarters.
ICA Group Wealth Management's BioMarin Pharmaceuticals position peaked at $31K in Q4 2022.
558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2024.

Based on ICA Group Wealth Management's 13F filing for Q2 2024, filed 8 Aug 2024.